- Home
- / Alector
Alector
Stock Price
$5.9
2023-08-25
Market Capitalization
$494.6 M
2023-08-25
Revenue
$133.6 M
FY, 2022
Alector Summary
Company Summary
- Overview
- Alector is a biopharmaceutical company that develops therapies for the treatment of neurodegenerative diseases. It offers AL001, a regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders, including frontotemporal dementia (FTD), Alzheimer’s disease, and Parkinson’s disease.
- Type
- Public
- Status
- Active
- Founded
- 2013
- HQ
- South San Francisco, CA, US | view all locations
- Website
- http://alector.com
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Sara Kenkare-Mitra, President and Head of Research and Development
Robert King, Chief Development Officer
Daniel Maslyar, Vice President, Clinical Development, Oncology
Operating MetricsView all
Patent Applications
380
26.7%
FY, 2021
Patent Families
50
25.0%
FY, 2021
Product Candidates
4
FY, 2019
LocationsView all
1 location detected
South San Francisco, CA HQ
United States
131 Oyster Point Blvd #600
Alector Financials
Summary Financials
- Revenue (Q2, 2023)
- $56.2M
- Net income (Q2, 2023)
- $1.4M
- Cash (Q2, 2023)
- $131.5M
- EBIT (Q2, 2023)
- ($3.6M)
- Enterprise value
- $404.0M